Enhabit, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Barbara Ann Jacobsmeyer
- Full Time Employees
- 10,600
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 6688 N. Central Expressway Dallas TX United States of America 75206
- IPO Date
- Jun 23, 2022
- CIK
- 0001803737
- Website
- ehab.com
- Similar Companies
- Business
- Enhabit, Inc. provides comprehensive home health and hospice services across the United States, operating in 34 states with 255 home health locations and 112 hospice locations. Its home health offerings include skilled nursing, physical, occupational and speech therapies, medical social work, home health aides, patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and chronic disease management for conditions such as diabetes, hypertension, arthritis, Alzheimer’s disease, and respiratory diseases. The hospice segment delivers end-of-life care with services including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual care, bereavement counseling, medication management, durable medical equipment, and aide and homemaker services. Enhabit targets Medicare-certified patients and operates as the fourth largest home health and the twelfth largest hospice provider nationally. Founded in 1998 and headquartered in Dallas, Texas, Enhabit was formerly the home health and hospice division of Encompass Health and rebranded to its current name in March 2022. Recent major company developments include the completion of a strategic review initiated in 2023, where after exploring potential sales or mergers, the Board confirmed continuing as an independent public company to enhance shareholder value. The company is actively pursuing operational efficiencies, new patient admissions growth, and payer contract negotiations while managing expense controls. In 2023, Enhabit acquired Specialty Home Health Care, Inc. for $3.1 million and expanded its Florida footprint through the acquisition of Southwest Florida Home Care, widening its presence to 22 home health locations in that state. Financially, Enhabit reported improved Adjusted EBITDA with a 6.7% year-over-year increase, significant reductions in bank debt totaling $25 million in Q1 2025, and raised its full-year 2025 revenue guidance to $1.06 billion to $1.073 billion with projected Adjusted EBITDA of $104 million to $108 million. Leadership transition plans are underway with the current CEO announcing intentions to step down by July 2026 or upon successor appointment, supported by an executive search firm. The company continues to focus on growth strategies in its hospice segment including organic expansions, new location openings, and enhanced analytics to improve quality and operational efficiency. Enhabit operates primarily in the home health and hospice industry segments, serving elderly and chronically ill patients requiring in-home care. It leverages advanced technology platforms and compassionate multidisciplinary clinical teams to deliver patient-centered care aiming to improve outcomes and patient comfort at home. The company’s strategic initiatives reflect a commitment to expanding service reach, enhancing financial performance, and maintaining strong operational and clinical quality standards nationally.
Enhabit Home Health & Hospice Announces New Chief Executive Officer
Fast-paced Momentum Stock Enhabit (EHAB) Is Still Trading at a Bargain
Enhabit (EHAB) Upgraded to Buy: Here's Why
Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of “Hold” from Brokerages
Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?
Enhabit Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enhabit, Inc. - EHAB
Enhabit Sets Stockholder Meeting Date of May 12, 2026, to Approve Transaction with Kinderhook
JPMorgan Chase & Co. Sells 271,731 Shares of Enhabit, Inc. $EHAB
Comparing Enhabit (NYSE:EHAB) & Selectis Health (OTCMKTS:GBCS)
8 Knots Management LLC Has $33.79 Million Position in Enhabit, Inc. $EHAB
Dynamic Technology Lab Private Ltd Has $253,000 Stake in Enhabit, Inc. $EHAB
Hidden Gems for Nervous Investors: 4 Safe Haven Stocks Flying Below the Radar
Agilon Health (NYSE:AGL) versus Enhabit (NYSE:EHAB) Head to Head Comparison
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—ACLX, VRE, EHAB, and CECO
Shareholder Investigation Launched by Kaskela Law Firm into Fairness of Enhabit, Inc. (NYSE: EHAB) Buyout Price; EHAB Investors Encouraged to Contact the Firm
Enhabit (EHAB) Matches Q4 Earnings Estimates
Enhabit Reports Fourth Quarter 2025 Financial Results
Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of “Hold” from Brokerages
Why Fast-paced Mover Enhabit (EHAB) Is a Great Choice for Value Investors
Enhabit (EHAB) Expected to Announce Earnings on Wednesday